LT3781561T - Metilą modifikuojančių fermentų moduliatoriai, kompozicijos ir jų naudojimas - Google Patents

Metilą modifikuojančių fermentų moduliatoriai, kompozicijos ir jų naudojimas

Info

Publication number
LT3781561T
LT3781561T LTEPPCT/US2019/027932T LTUS2019027932T LT3781561T LT 3781561 T LT3781561 T LT 3781561T LT US2019027932 T LTUS2019027932 T LT US2019027932T LT 3781561 T LT3781561 T LT 3781561T
Authority
LT
Lithuania
Prior art keywords
compositions
methyl
modifying enzyme
enzyme modulators
modulators
Prior art date
Application number
LTEPPCT/US2019/027932T
Other languages
English (en)
Lithuanian (lt)
Inventor
Alexandre Côté
Victor GEHLING
Avinash KHANNA
Ludivine MOINE
Jacob STUCKEY
Original Assignee
Constellation Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Constellation Pharmaceuticals, Inc. filed Critical Constellation Pharmaceuticals, Inc.
Publication of LT3781561T publication Critical patent/LT3781561T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
LTEPPCT/US2019/027932T 2018-04-18 2019-04-17 Metilą modifikuojančių fermentų moduliatoriai, kompozicijos ir jų naudojimas LT3781561T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862659408P 2018-04-18 2018-04-18
PCT/US2019/027932 WO2019204490A1 (en) 2018-04-18 2019-04-17 Modulators of methyl modifying enzymes, compositions and uses thereof

Publications (1)

Publication Number Publication Date
LT3781561T true LT3781561T (lt) 2024-07-10

Family

ID=66429588

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2019/027932T LT3781561T (lt) 2018-04-18 2019-04-17 Metilą modifikuojančių fermentų moduliatoriai, kompozicijos ir jų naudojimas

Country Status (34)

Country Link
US (4) US10689371B2 (enExample)
EP (2) EP4421072A1 (enExample)
JP (2) JP7256823B2 (enExample)
KR (2) KR102798145B1 (enExample)
CN (2) CN111989325B (enExample)
AR (1) AR114793A1 (enExample)
AU (1) AU2019255310B2 (enExample)
BR (1) BR112020021194A2 (enExample)
CL (1) CL2020002698A1 (enExample)
CO (1) CO2020014217A2 (enExample)
CR (1) CR20200553A (enExample)
DK (1) DK3781561T3 (enExample)
EA (1) EA202092490A1 (enExample)
ES (1) ES2983344T3 (enExample)
FI (1) FI3781561T3 (enExample)
HR (1) HRP20240793T1 (enExample)
HU (1) HUE066783T2 (enExample)
IL (1) IL278013B2 (enExample)
LT (1) LT3781561T (enExample)
MA (1) MA52288B1 (enExample)
MD (1) MD3781561T2 (enExample)
MX (1) MX2020010999A (enExample)
MY (1) MY208662A (enExample)
PE (1) PE20201448A1 (enExample)
PH (1) PH12020551578A1 (enExample)
PL (1) PL3781561T3 (enExample)
PT (1) PT3781561T (enExample)
RS (1) RS65621B1 (enExample)
SG (1) SG11202009438UA (enExample)
SI (1) SI3781561T1 (enExample)
SM (1) SMT202400233T1 (enExample)
TW (1) TWI828677B (enExample)
UA (1) UA127357C2 (enExample)
WO (1) WO2019204490A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020010999A (es) 2018-04-18 2021-01-20 Constellation Pharmaceuticals Inc Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos.
EP3797108B1 (en) 2018-05-21 2022-07-20 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
KR102689665B1 (ko) 2019-02-19 2024-07-31 한미약품 주식회사 신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도
PE20220562A1 (es) * 2019-07-24 2022-04-13 Constellation Pharmaceuticals Inc Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida
KR20220041130A (ko) * 2019-07-24 2022-03-31 콘스텔레이션 파마슈티칼스, 인크. 암 치료를 위한 병용 요법에서의 ezh2 억제
WO2021180235A1 (zh) * 2020-03-13 2021-09-16 四川海思科制药有限公司 Zeste增强子同源物2抑制剂及其用途
CN113666920B (zh) * 2020-04-14 2025-10-03 浙江华海药业股份有限公司 苯并恶唑类化合物制备方法及其在医药领域的应用
IL299730A (en) * 2020-07-08 2023-03-01 Daiichi Sankyo Co Ltd Production method of 1,3-benzodioxole derivative
WO2022109106A1 (en) * 2020-11-18 2022-05-27 Constellation Pharmaceuticals, Inc Ezh2 inhibition therapies for the treatment of androgen receptor mutated prostate cancers
KR102872076B1 (ko) 2021-01-11 2025-10-15 주식회사 엘지에너지솔루션 전극 슬러리의 유량 제어가 가능한 전극 슬러리 코팅 시스템 및 이를 이용한 전극 슬러리 코팅 방법
AU2023206700B2 (en) * 2022-01-14 2026-03-12 Dong Wha Pharm. Co., Ltd. 1,3-benzodioxole derivative compound and pharmaceutical composition comprising same
CN116496263A (zh) * 2022-01-27 2023-07-28 江苏天士力帝益药业有限公司 Ezh1/2抑制剂及其制备和抗肿瘤治疗中的应用
WO2023217018A1 (zh) * 2022-05-07 2023-11-16 贝达药业股份有限公司 Ezh2抑制剂及其在医药上的应用
KR20250023483A (ko) 2022-06-13 2025-02-18 트리라인 바이오사이언시스, 인크. 퀴놀론 bcl6 이작용성 분해제
AU2023295387A1 (en) 2022-06-13 2025-01-09 Treeline Biosciences, Inc. 1,8-naphthyridin-2-one heterobifunctional bcl6 degraders
IL318787A (en) 2022-08-17 2025-04-01 Incyte Corp Treatment including ANTI-CD19 antibodies and EZH2 modulators
EP4740948A1 (en) * 2023-07-06 2026-05-13 Dong Wha Pharm. Co., Ltd. Pharmaceutical composition comprising 1,3-benzodioxole derivative compound
TW202542136A (zh) * 2023-12-15 2025-11-01 大陸商格物生物技術（江蘇）有限公司 １，３－苯并二氧雜環戊烯衍生物以及其用途
WO2026077358A1 (en) * 2024-10-07 2026-04-16 Constellation Pharmaceuticals, Inc. Solid forms and salts of 7-chloro-2- (4- (3-methoxyazetidin-1-yl) cyclohexyl) -2, 4-dimethyl-n- ( (6-methyl-4- (methylthio) -2-oxo-1, 2-dihydropyridin-3-yl) methyl) benzo [d] [1, 3] dioxole-5-carboxamide

Family Cites Families (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6317850A (ja) 1986-07-11 1988-01-25 Fuji Photo Film Co Ltd ３−フエノキシカテコ−ル類の製造方法
CA2004670A1 (en) 1988-12-08 1990-06-08 Jan Hartog Anxiolytically active piperazine derivatives
JPH02255673A (ja) 1989-03-27 1990-10-16 Fuji Photo Film Co Ltd ４―アリールオキシー１，３―ベンゾジオキソール類およびその製造方法
JPH02255674A (ja) 1989-03-27 1990-10-16 Fuji Photo Film Co Ltd ４―アリールオキシ―１，３―ベンゾジオキソール類およびその製造方法
JPH02269352A (ja) 1989-04-10 1990-11-02 Fuji Photo Film Co Ltd 感光材料
JP2537682B2 (ja) 1989-04-21 1996-09-25 富士写真フイルム株式会社 ３―アリ―ルオキシカテコ―ル類の製造方法
US5296497A (en) 1989-05-16 1994-03-22 Duphar International Research B.V. 3,4-dehydropiperidine derivatives having psychotropic activity
JPH03130280A (ja) 1989-10-17 1991-06-04 Fuji Photo Film Co Ltd ４―アリールオキシ―１，３―ベンゾジオキソール類の製造方法
JP2816492B2 (ja) 1990-05-23 1998-10-27 コニカ株式会社 ハロゲン化銀写真感光材料
JPH0446175A (ja) 1990-06-14 1992-02-17 Fuji Photo Film Co Ltd ５―ヒドロキシ―３，４―メチレンジオキシ安息香酸誘導体の製造法
JPH0641038A (ja) 1992-07-17 1994-02-15 Mitsubishi Kasei Corp カルボン酸誘導体
DE4326151A1 (de) 1993-08-04 1995-02-09 Hoechst Ag Aromatische Verbindungen und ihre Verwendung in flüssigkristallinen Mischungen
US5629200A (en) 1993-11-18 1997-05-13 Daicel Chemical Industries, Ltd. Production of optically active 2-amino-1-phenylethanol derivatives by asymetrical assimilation
US5514505A (en) 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
ATE478672T1 (de) 1996-01-29 2010-09-15 Univ California Methode zur behandlung sexueller fehlfunktionen
HUP9902088A2 (hu) 1996-05-14 2001-04-28 American Home Products Corporation Szubsztituált 1,3-benzodioxol-származékok, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
US5968929A (en) 1996-10-30 1999-10-19 Schering Corporation Piperazino derivatives as neurokinin antagonists
JPH10287654A (ja) 1997-04-11 1998-10-27 Nissan Chem Ind Ltd ピラゾロン誘導体及び除草剤
US6166008A (en) 1997-10-27 2000-12-26 Cortex Pharmaceuticals, Inc. Treatment of schizophrenia with ampakines and neuroleptics
CZ303899B6 (cs) 1998-09-29 2013-06-19 Wyeth Holdings Corporation Substituovaný 3-kyanochinolin, zpusob jeho prípravy a farmaceutická kompozice s jeho obsahem
EP1384713B1 (en) * 1998-12-23 2008-10-15 SmithKline Beecham Corporation 4-amino-azepan-3-one derivatives as protease inhibitors
US7977333B2 (en) 2000-04-20 2011-07-12 Bayer Healthcare Llc Substituted pyridines and pyridazines with angiogenesis inhibiting activity
US6451814B1 (en) 2000-07-17 2002-09-17 Wyeth Heterocyclic β-3 adrenergic receptor agonists
AU2001278609B2 (en) 2000-08-21 2005-04-14 Astrazeneca Ab Quinazoline derivatives
WO2002016327A1 (en) 2000-08-23 2002-02-28 The Procter & Gamble Company Benzimidazoles and analogues and their use as neutrophil inhibitors
RU2324686C2 (ru) 2000-08-24 2008-05-20 Юнивесити Оф Питсбэг ПРОИЗВОДНЫЕ ТИОФЛАВИНА, СВЯЗЫВАЮЩИЕ АМИЛОИД, СПОСОБ ОБНАРУЖЕНИЯ in vivo ОТЛОЖЕНИЙ АМИЛОИДА И СПОСОБ РАСПОЗНАВАНИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА
AUPR255401A0 (en) 2001-01-16 2001-02-08 Novogen Research Pty Ltd Regulation of lipids and/or bone density and compositions therefor
WO2002074307A1 (en) 2001-03-16 2002-09-26 Novogen Research Pty Ltd Treatment of restenosis
WO2002081443A1 (en) 2001-04-09 2002-10-17 Chiron Corporation Novel guanidino compounds
ATE409185T1 (de) 2001-04-19 2008-10-15 Astrazeneca Ab Chinazolin derivate
DE10148618B4 (de) 2001-09-25 2007-05-03 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
DE10148617A1 (de) 2001-09-25 2003-04-24 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
AUPR846401A0 (en) 2001-10-25 2001-11-15 Novogen Research Pty Ltd 6-Hydroxy isoflavones, derivatives and medicaments involving same
CA2470427C (en) 2001-12-21 2012-07-10 Cytokinetics, Incorporated Compositions and methods for treating heart failure
EP1463719A2 (en) 2002-01-08 2004-10-06 Eisai Co., Ltd Eponemycin and epoxomicin analogs and uses thereof
CA2473740A1 (en) 2002-01-18 2003-07-31 David Solow-Cordero Methods of treating conditions associated with an edg receptor
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
EP1503751A4 (en) 2002-04-09 2007-08-01 Novogen Res Pty Ltd THERAPEUTIC PROCESSES AND COMPOSITIONS WITH ISOFLAV-3-EN AND ISOFLAVAN STRUCTURES
DE10219294A1 (de) 2002-04-25 2003-11-13 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
AU2003250117B2 (en) 2002-07-29 2007-05-10 F. Hoffmann-La Roche Ag Novel benzodioxoles
AU2002951271A0 (en) 2002-09-06 2002-09-19 Novogen Research Pty Ltd Repair of dna mutagenic damage
CZ2005181A3 (cs) 2002-09-23 2005-08-17 Novogen Research Pty Ltd Léčba stárnutí pokožky vlivem světla a aktinického poškození pokožky
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
CA2531140C (en) 2003-07-28 2013-06-18 Applied Research Systems Ars Holding N.V. 2-imino-4-(thio) oxo-5-polycyclovinylazolines for use as pi3 kinase inhibitors
AU2004276337B2 (en) 2003-09-24 2009-11-12 Methylgene Inc. Inhibitors of histone deacetylase
CA2546643A1 (en) 2003-11-18 2005-06-02 Novogen Research Pty Ltd Isoflavonoid prodrugs, compositions thereof and therapeutic methods involving same
CN101123958A (zh) 2003-11-19 2008-02-13 诺沃根研究股份有限公司 联合放射疗法与化学疗法的组合物和方法
CN1930128A (zh) 2004-01-16 2007-03-14 惠氏公司 受体酪氨酸激酶抑制剂的喹啉中间体及其合成
TW200538127A (en) 2004-04-07 2005-12-01 Millennium Pharm Inc PGD2 receptor antagonists for the treatment of inflammatory diseases
US20050245529A1 (en) 2004-04-14 2005-11-03 Boehringer Ingelheim International Gmbh Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
WO2005112932A2 (en) 2004-05-07 2005-12-01 Exelixis, Inc. Raf modulators and methods of use
MXPA06013250A (es) 2004-05-14 2007-02-28 Abbott Lab Inhibidores de quinasa como agentes terapeuticos.
ITMI20041347A1 (it) 2004-07-05 2004-10-05 Italfarmaco Spa Derivati di alfa-amminoacidi ad attivita'antiinfiammatoria
SE0401971D0 (sv) 2004-08-02 2004-08-02 Astrazeneca Ab Piperidne derivatives
MX2007004302A (es) 2004-10-12 2007-06-07 Applied Research Systems Inhibidores de pi3 cinasa gamma para el tratamiento de anemia.
SE0402635D0 (sv) 2004-10-29 2004-10-29 Astrazeneca Ab Chemical compounds
JP2006145294A (ja) 2004-11-17 2006-06-08 Univ Nagoya 蛍光標識を行うラベル化試薬、リガンドを表面にもつ基材の製造方法及びラベル化試薬を用いた測定方法
US7524870B2 (en) 2004-12-03 2009-04-28 Hoffmann-La Roche Inc. Biaryloxymethylarenecarboxylic acids as glycogen synthase activators
PL1859793T3 (pl) 2005-02-28 2011-09-30 Eisai R&D Man Co Ltd Nowe połączone zastosowanie związku sulfonamidowego w leczeniu choroby nowotworowej
US20060223846A1 (en) 2005-03-08 2006-10-05 Dyatkin Alexey B Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists
EP1893605A2 (en) 2005-03-31 2008-03-05 AstraZeneca AB Saminopyrimidine derivates with tie2 inhibiting activity
CA2604836A1 (en) 2005-04-08 2006-10-19 Bayer Pharmaceuticals Corporation Pyrimidine derivatives and their use in the treatment of cancer
SI1881823T1 (sl) 2005-05-17 2015-04-30 Sarcode Bioscience Inc. Sestavki in postopki za zdravljenje bolezni oäśesa
WO2006127205A2 (en) 2005-05-25 2006-11-30 Wyeth Methods of preparing 3-cyano-quinolines and intermediates made thereby
JPWO2006129609A1 (ja) 2005-05-30 2009-01-08 塩野義製薬株式会社 ２−ナフチルイミノ−５，５−ジ置換−１，３−チアジン誘導体
US8017635B2 (en) 2005-06-02 2011-09-13 Fmc Corporation Phenylalkyl substituted heteroaryl derivatives
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
US7956050B2 (en) 2005-07-15 2011-06-07 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
CA2616224A1 (en) 2005-07-21 2007-02-01 Paratek Pharmaceuticals, Inc. 10-substituted tetracyclines and methods of use thereof
EP1928461B1 (en) 2005-08-04 2012-01-04 Janssen Pharmaceutica NV Pyrimidine compounds as serotonin receptor modulators
US7737166B2 (en) 2005-08-17 2010-06-15 Daiichi Sankyo Company, Limited Antifungal bicyclic hetero ring compounds
WO2007081630A2 (en) 2005-12-21 2007-07-19 Janssen Pharmaceutica, N.V. Substituted pyrimidinyl kinase inhibitors
CN101007798B (zh) 2006-01-24 2011-01-26 中国人民解放军军事医学科学院毒物药物研究所 苯并间二氧杂环戊烯衍生物及其制备方法和医药用途
PL1996180T3 (pl) 2006-03-23 2012-05-31 Biota Scient Management Pty Ltd Pochodne benzamidu i pirydyloamidu jako czynniki antybakteryjne
NZ571288A (en) 2006-05-30 2011-05-27 Neurosearch As Novel 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives and their medical use
US20100035877A1 (en) 2006-06-26 2010-02-11 Katz David M Methods and compositions for treating pathologies associated with bdnf signaling
WO2008029168A2 (en) 2006-09-08 2008-03-13 Summit Corporation Plc Treatment of duchenne muscular dystrophy
CA2668008A1 (en) 2006-10-30 2008-05-08 Novogen Research Pty Ltd Prevention and reversal of chemotherapy-induced peripheral neuropathy
RU2333211C1 (ru) 2006-11-01 2008-09-10 Институт физиологически активных веществ Российской Академии наук N,n`-замещенные 3, 7-диазабицикло[3.3.1]нонаны, обладающие фармакологической активностью, фармацевтические композиции на их основе и способ их применения
BRPI0811204A8 (pt) 2007-05-10 2015-09-22 Bristol Myers Squibb Co Tetra-hidroibenzo-1,4-diazepinas substituídas por arila e heteroarila e uso das mesmas para bloquear a recaptação de norepinefrina, dopamina e serotonina
BRPI0704074B8 (pt) 2007-08-29 2021-05-25 Univ Estadual Paulista Julio De Mesquita Filho Unesp derivados piperidínicos da (-)-cassina e (-)-spectalina, composições farmacêuticas contendo os mesmos e processos para sua preparação
CA2702984C (en) 2007-10-19 2017-04-11 Sarcode Corporation Compositions and methods for treatment of diabetic retinopathy
KR20100132550A (ko) 2008-04-16 2010-12-17 포톨라 파마슈티컬스, 인코포레이티드 ｓｙｋ 또는 ＪＡＫ 키나제 억제제로서의 ２,６－디아미노-피리미딘－５－일－카르복스아미드
AU2009271436B2 (en) 2008-06-23 2014-04-03 Janssen Pharmaceutica Nv Piperidyl acrylamide antagonists of CCR2
US20110207784A1 (en) 2008-08-14 2011-08-25 The United States Of America, As Represented By The Secretary, Oxadiazole-2-oxides as antischistosomal agents
JP2010254629A (ja) 2009-04-27 2010-11-11 Bayer Cropscience Ag 光学活性アゾリン誘導体
TW201109327A (en) 2009-05-28 2011-03-16 Otsuka Pharma Co Ltd Heterocyclic compound
WO2011004018A1 (en) 2009-07-10 2011-01-13 Vivalis Substituted pyrrolidinone as inhibitors of hepatitis c ns5b polymerase, the pharmaceutical composition thereof and their therapeutic use
RU2417082C2 (ru) 2009-07-14 2011-04-27 Учреждение Российской Академии Наук Институт Физиологически Активных Веществ Ран (Ифав Ран) Средство для восстановления утраченной памяти в норме и патологии у пациентов всех возрастных групп на основе n, n'-замещенных 3, 7-диазабицикло[3.3.1]нонанов, фармацевтическая композиция на его основе и способ ее применения
EP2513268B1 (en) 2009-12-17 2019-02-20 The Lubrizol Corporation Use of an aromatic compound as antiwear agent in lubricants
CA2788155C (en) 2010-01-27 2018-04-24 AB Pharma Ltd. Polyheterocyclic compounds highly potent as hcv inhibitors
CN101851218B (zh) 2010-04-27 2014-10-15 沈阳药科大学 4,5-二取代芳基异硒唑类衍生物及其用途
MX2012012966A (es) 2010-05-07 2013-01-22 Glaxosmithkline Llc Indoles.
US20130338153A1 (en) 2010-06-10 2013-12-19 Afraxis, Inc. 8-(2'-heterocycyl)pyrido[2.3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
ES2526124T3 (es) 2010-06-16 2015-01-07 Cymabay Therapeutics, Inc. Agonistas del receptor GPR120 y sus usos
JP6174997B2 (ja) 2010-06-24 2017-08-02 レオ ファーマ アクティーゼルスカブ ホスホジエステラーゼ阻害剤としてのベンゾジオキソールまたはベンゾジオキセピンヘテロ環化合物
WO2012013725A1 (en) 2010-07-28 2012-02-02 Medizinische Universität Wien Vinylogous chalcone derivatives and their medical use
US9132136B2 (en) 2010-08-02 2015-09-15 Hoffmann-La Roche Inc. Pharmaceutical combination
EP2617715A4 (en) 2010-09-17 2014-02-26 Taisho Pharmaceutical Co Ltd GLYCINTRANSPORTERHEMMER
WO2012045196A1 (en) 2010-10-09 2012-04-12 Abbott Laboratories Phosphoglycerate kinase inhibitors
WO2012118812A2 (en) 2011-02-28 2012-09-07 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
US8802673B2 (en) 2011-03-24 2014-08-12 Hoffmann-La Roche Inc Heterocyclic amine derivatives
JO3363B1 (ar) 2011-04-13 2019-03-13 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
DE102011017046A1 (de) 2011-04-14 2012-10-18 Till Photonics Gmbh Umschaltbare Mikroskopanordnung mit mehreren Detektoren
WO2013025484A1 (en) 2011-08-12 2013-02-21 Lapchak Paul A Polyphenol analogs to treat ischemia
US8791108B2 (en) 2011-08-18 2014-07-29 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
JPWO2013065835A1 (ja) 2011-11-04 2015-04-02 味の素株式会社 糖尿病治療用医薬組成物
NZ727015A (en) 2012-01-25 2017-12-22 Vertex Pharma Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
US9085583B2 (en) 2012-02-10 2015-07-21 Constellation—Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP2828245A1 (en) 2012-03-21 2015-01-28 Rutgers, The State University of New Jersey Antimicrobial agents
ES2617379T3 (es) 2012-04-13 2017-06-16 Epizyme, Inc. Forma de sal de un inhibidor de histona metiltransferasa EZH2 humana
EP2836216B1 (en) 2012-04-13 2022-06-08 Epizyme, Inc. Combination therapy for treating cancer
US9562041B2 (en) 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
RU2509770C2 (ru) 2012-06-22 2014-03-20 Общество с ограниченной ответственностью "Молекулярные Технологии" Новые химические соединения производные 2,4-диамино-1,3,5-триазина для профилактики и лечения заболеваний человека и животных
JPWO2014034898A1 (ja) 2012-08-30 2016-08-08 日本新薬株式会社 ピリジン誘導体及び医薬
WO2014066435A1 (en) 2012-10-22 2014-05-01 City Of Hope Etp derivatives
RU2015127822A (ru) 2012-12-13 2017-01-16 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Ингибиторы энхансера гомолога 2 белка zeste
PL2953941T3 (pl) 2013-02-11 2017-11-30 Constellation Pharmaceuticals, Inc. Modulatory enzymów modyfikujących metyl, ich kompozycje i zastosowania
JP6378308B2 (ja) 2013-03-13 2018-08-22 ボストン バイオメディカル， インコーポレイテッド がんの処置のための、がん幹細胞経路キナーゼの阻害剤としての３−（アリールまたはヘテロアリール）メチレンインドリン−２−オン誘導体
WO2014177464A2 (en) 2013-04-30 2014-11-06 Heinrich-Heine-Universität Düsseldorf Inhibitors of nhr2 and/or runx1/eto-tetramerization
KR20150027922A (ko) 2013-09-04 2015-03-13 주식회사 대웅제약 신규한 항진균성 피리디닐하이드라자이드 유도체
AU2014317663B2 (en) 2013-09-09 2018-02-08 Youngene Therapeutics Co., Ltd. C-aryl glucoside derivative, preparation method for same, and medical applications thereof
WO2015069110A1 (en) 2013-11-07 2015-05-14 Aapa B.V. Multiple d2 a(nta)gonists/h3 antagonists for treatment of cns-related disorders
PL3121175T3 (pl) * 2014-03-17 2020-06-01 Daiichi Sankyo Company, Limited Pochodne 1,3-benzodioksolu jako inhibitory ezh1 i/lub ezh2
AP2016009605A0 (en) 2014-06-17 2016-12-31 Pfizer Substituted dihydroisoquinolinone compounds
EP3191463B1 (en) 2014-09-11 2019-10-30 Piramal Enterprises Limited Fused heterocyclic compounds as gpr120 agonists
MA40848A (fr) 2014-10-28 2021-05-05 Glaxosmithkline Ip No 2 Ltd Inhibiteurs d'ezh2 (enhancer of zeste homolog 2)
TW201636344A (zh) 2014-12-05 2016-10-16 美國禮來大藥廠 Ｅｚｈ２抑制劑
US20180037568A1 (en) * 2015-02-13 2018-02-08 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
MX391720B (es) 2015-04-20 2025-03-21 Epizyme Inc Terapia combinada para tratar cáncer.
CA2993605C (en) 2015-07-30 2020-01-07 The University Of Tokyo 1,3-benzodioxole derivatives for the treatment or prevention of adult t cell leukemia/lymphoma
CA2994394A1 (en) 2015-08-03 2017-02-09 Constellation Pharmaceuticals, Inc. Ezh2 inhibitors and modulation of regulatory t-cell function
WO2017040190A1 (en) 2015-08-28 2017-03-09 Constellation Pharmaceuticals, Inc. Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide
JP6893517B2 (ja) 2016-01-13 2021-06-23 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング ３−（（ヘテロ−）アリール）−アルキル−８−アミノ−２−オキソ−１，３−ジアザ−スピロ−［４．５］−デカン誘導体
MX2018009633A (es) 2016-02-09 2018-12-17 Inventisbio Inc Inhibidor de indoleamina-2,3-dioxigenasa (ido).
US20170355708A1 (en) * 2016-06-09 2017-12-14 Cadent Therapeutics, Inc. Potassium channel modulators
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
CN106727549A (zh) 2016-11-26 2017-05-31 李�荣 一种治疗抑郁症的药物
CN108314677B (zh) 2017-01-17 2020-06-30 安徽中科拓苒药物科学研究有限公司 一种ezh2抑制剂及其用途
BR112019014924A2 (pt) 2017-01-19 2020-03-31 St. Marianna University School Of Medicine Composição farmacêutica usada para o tratamento de mielopatia associada ao htlv-1
US11466020B2 (en) 2017-03-17 2022-10-11 Cornell University Compounds and compositions for inhibition and elimination of Zika infection and uses for same
CN110869358A (zh) 2017-05-25 2020-03-06 亚瑞克西斯制药公司 Kras的共价抑制剂
EP3700527A4 (en) 2017-10-25 2021-03-10 Children's Medical Center Corporation PAPD5 INHIBITORS AND METHOD OF USING THEM
GB201718285D0 (en) 2017-11-03 2017-12-20 Discuva Ltd Antibacterial Compounds
JP2021035913A (ja) 2017-12-21 2021-03-04 石原産業株式会社 Ｎ−メトキシアミド化合物又はその塩、及びそれらを含有する農園芸用殺菌剤
CA3125731A1 (en) 2018-01-12 2019-07-18 KDAc Therapeutics, Inc. Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer
JP2019168611A (ja) 2018-03-23 2019-10-03 株式会社Adeka 光学フィルタ
WO2019191558A1 (en) 2018-03-30 2019-10-03 San Diego State University (SDSU) Foundation, dba San Diego State University Research Foundation Methods for mitigating and preventing proteostasis-based injuries
MX2020010999A (es) 2018-04-18 2021-01-20 Constellation Pharmaceuticals Inc Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos.
EP3797108B1 (en) 2018-05-21 2022-07-20 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
KR102689665B1 (ko) 2019-02-19 2024-07-31 한미약품 주식회사 신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도
PE20220562A1 (es) 2019-07-24 2022-04-13 Constellation Pharmaceuticals Inc Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida
KR20220041130A (ko) 2019-07-24 2022-03-31 콘스텔레이션 파마슈티칼스, 인크. 암 치료를 위한 병용 요법에서의 ezh2 억제

Also Published As

Publication number Publication date
DK3781561T3 (da) 2024-06-17
ES2983344T3 (es) 2024-10-22
KR102798145B1 (ko) 2025-04-22
PH12020551578A1 (en) 2021-09-13
MA52288A (fr) 2021-04-07
AU2019255310A1 (en) 2020-10-15
SI3781561T1 (sl) 2024-08-30
BR112020021194A2 (pt) 2021-03-23
EP4421072A1 (en) 2024-08-28
EP3781561A1 (en) 2021-02-24
RS65621B1 (sr) 2024-07-31
US11274095B2 (en) 2022-03-15
US20260234133A1 (en) 2026-08-13
WO2019204490A1 (en) 2019-10-24
EA202092490A1 (ru) 2020-12-23
US10689371B2 (en) 2020-06-23
PT3781561T (pt) 2024-06-18
IL278013B2 (en) 2024-01-01
FI3781561T3 (fi) 2024-06-13
JP7256823B2 (ja) 2023-04-12
US20190322651A1 (en) 2019-10-24
CN111989325B (zh) 2025-02-25
US20200317651A1 (en) 2020-10-08
PL3781561T3 (pl) 2024-07-22
PE20201448A1 (es) 2020-12-10
HRP20240793T1 (hr) 2024-09-13
HUE066783T2 (hu) 2024-09-28
US12612390B2 (en) 2026-04-28
US20240116905A1 (en) 2024-04-11
CN119954787A (zh) 2025-05-09
CA3098428A1 (en) 2019-10-24
TW202003505A (zh) 2020-01-16
CR20200553A (es) 2021-04-08
MX2020010999A (es) 2021-01-20
KR20210003160A (ko) 2021-01-11
SG11202009438UA (en) 2020-11-27
AR114793A1 (es) 2020-10-14
CO2020014217A2 (es) 2021-03-08
TWI828677B (zh) 2024-01-11
MY208662A (en) 2025-05-22
AU2019255310B2 (en) 2022-11-24
SMT202400233T1 (it) 2024-07-09
KR20250073166A (ko) 2025-05-27
MA52288B1 (fr) 2024-07-31
JP2021522166A (ja) 2021-08-30
EP3781561B1 (en) 2024-03-13
JP2023082132A (ja) 2023-06-13
IL278013B1 (en) 2023-09-01
MD3781561T2 (ro) 2025-02-28
UA127357C2 (uk) 2023-07-26
CL2020002698A1 (es) 2021-01-15
IL278013A (en) 2020-11-30
CN111989325A (zh) 2020-11-24

Similar Documents

Publication Publication Date Title
IL283169A (en) Crispr-cas12j enzyme and system
DK3781561T3 (da) Modulatorer af methylmodificerende enzymer, sammensætninger og anvendelser deraf
DK3580561T3 (da) Hla-baserede metoder, sammensætninger og anvendelse heraf
PT3635009T (pt) Composições e métodos para internalização de enzimas
EP3633034A4 (en) MODIFIED Cas9 PROTEIN AND USE THEREOF
DK3804737T3 (da) Sammensætninger omfattende bakteriestammer
IL281171A (en) Cellulose-synthase-like enzymes and their uses
IL282178A (en) Products, uses & methods
EP3790861A4 (en) SENOLYTIC COMPOSITIONS AND THEIR USES
BR112017005507A2 (pt) composições que compreendem células recombinantes de bacillus e um fungicida.
EP3452435A4 (en) HIGHLY EFFECTIVE AND MULTIFUNCTIONAL MICROBIAL COMPOSITIONS AND USES
LT3128005T (lt) Sirp-alfa varianto konstruktai, ir jų panaudojimas
BR112017005504A2 (pt) composições que compreendem células recombinantes de bacillus e um inseticida.
PL3380508T3 (pl) Termostabilny polipeptyd fgf2, jego zastosowanie
BR112017005379A2 (pt) composições que compreendem células recombinantes de bacillus e um fungicida.
MA54386A (fr) Modulateurs de trex1
EP3702441A4 (en) LYOPHILIZED COMPOSITION OF MICROORGANISMS
EP3902870C0 (en) BACTERIAL CELLULOSE FORMULATIONS, METHODS AND USES THEREOF
EP3821026A4 (en) MANIPULATED ENZYME VARIANTS OF PHOSPHOPENTOMUTASE
DK3630968T3 (da) Enzymer til glycananalyse
LT3638271T (lt) Kompozicijos, apimančios bakterines padermes
EP3573974C0 (en) RORGAMMA MODULATORS AND THEIR USES
EP3562837A4 (en) MODIFIED LYSINE DECARBOXYLASE ENZYMES
EP3629742A4 (en) Bacterial inoculants
LT3713546T (lt) Skysta kompozicija, apimani paeonolį ir apokininą